drugset / Trial / NCT05490082

Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation

NCT05490082

Phase 3 Unknown 100 enrolled Mansoura University
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized controlled study to compare the efficacy of mirabegron, solifenacin and propevirine for treatment of Lower urinary tract symptoms during intravesical BCG installation

Timeline

Start
2022-03-01
Primary completion
2023-03
Completion
2023-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirabegron Other / unclassified 50 mg Oral
Comparator Propevirine Unknown 15 mg Oral
Comparator Solifenacin Small molecule 10 mg Oral